Glycopeptide use at four university hospitals in southern Germany

被引:9
作者
Kern, WV
de With, K
Trautmann, M
Kern, P
Gonnermann, C
机构
[1] Univ Hosp, Div Infect Dis, Dept Med 2, D-79106 Freiburg, Germany
[2] Univ Hosp, Sect Infect Dis & Clin Immunol, D-89070 Ulm, Germany
[3] Med Ctr, D-89070 Ulm, Germany
[4] Univ Hosp, Sect Hosp Hyg, D-89070 Ulm, Germany
[5] Univ Hosp, Hosp Pharm, VZM, D-89070 Ulm, Germany
关键词
D O I
10.1007/s15010-002-2161-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Excessive use of glycopeptide antibiotics may enhance the risk of glycopeptide resistance among enterococci and staphylococci, but there is Little data on the use of these antibiotics in German hospitals. Methods: Hospital pharmacy records for the years 1992 to 1994 were evaluated. The number of defined daily doses (DDD) per 100 patient days was calculated to compare glycopeptide use between four state university hospitals. At one of the hospitals with comparatively tow glycopeptide usage but an active antimicrobial management program, data were prospectively evaluated for 1995 to 2000 to assess the variation of glycopeptide use over time. Results: The 3-year averages in glycopeptide use for the four hospitals ranged between 1.03 and 3.14 DDD/100 patient days. In at four hospitals, glycopeptide use was higher in the medical service (range, 1.59-7.26) than in the surgical service (range, 0.66-4.39). Active antimicrobial management in one of the hospitals was associated with containment of glycopeptide consumption in the medical and surgical service at < 1.5 DDD/100 patient days in the Last 3 years. Conclusion: Glycopeptide use differs considerably at tertiary care hospitals in southern Germany, but use of < 1.5 DDD/100 patient days in both surgical as well as medical tertiary care hospital departments appears achievable.
引用
收藏
页码:262 / 266
页数:5
相关论文
共 30 条
[21]  
Kwan T, 1999, CLIN INVEST MED, V22, P256
[22]   Improving the appropriateness of vancomycin use by sequential interventions [J].
Lipsky, BA ;
Baker, CA ;
McDonald, LL ;
Suzuki, NT .
AMERICAN JOURNAL OF INFECTION CONTROL, 1999, 27 (02) :84-90
[23]  
MISAN GMH, 1990, EUR J CLIN PHARMACOL, V39, P457
[24]   Glycopeptide prescribing in a tertiary referral paediatric hospital and applicability of Hospital Infection Control Practices Advisory Committee (HICPAC) guidelines to children [J].
Nourse, G ;
Byrne, C ;
Leonard, L ;
Butler, K .
EUROPEAN JOURNAL OF PEDIATRICS, 2000, 159 (03) :193-197
[25]  
NUCCI M, 1999, 39 ICAAC 1999 SAN FR, P599
[26]   Vancomycin and teicoplanin use in Victorian hospitals [J].
Robertson, MB ;
Dartnell, JGA ;
Korman, TM .
MEDICAL JOURNAL OF AUSTRALIA, 1999, 171 (03) :127-131
[27]   Vancomycin use in pediatric neurosurgery patients [J].
Shah, SS ;
Sinkowitz-Cochran, RL ;
Keyserling, HL ;
Jarvis, WR .
AMERICAN JOURNAL OF INFECTION CONTROL, 1999, 27 (06) :482-487
[28]   Epidemiology of vancomycin usage at a children's hospital, 1993 through 1995 [J].
Sinkowitz, RL ;
Keyserling, H ;
Walker, TJ ;
Holland, J ;
Jarvis, WR .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (05) :485-489
[29]   Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center [J].
Solomon, DH ;
Van Houten, L ;
Glynn, RJ ;
Baden, L ;
Curtis, K ;
Schrager, H ;
Avorn, J .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (15) :1897-1902
[30]  
ZAVASKY DM, 1999, 39 ICAAC 1999 SAN FR, P736